Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:CRTX NASDAQ:EDIT NASDAQ:ORTX NASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.76-6.8%$2.11$0.87▼$6.37$299.59M0.991.22 million shs580,712 shsCRTXCortexyme$1.60$1.69$1.78▼$40.66$48.24M1.4620,672 shs88,479 shsEDITEditas Medicine$2.83+6.0%$2.74$0.91▼$4.12$240.09M2.161.14 million shs2.57 million shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/ASWTXSpringWorks Therapeutics$46.99$46.90$28.21▼$62.00$3.54B0.682.66 million shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-6.76%-1.43%+22.67%+89.04%-51.41%CRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%EDITEditas Medicine+5.99%+2.54%-6.60%+20.43%-26.11%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%SWTXSpringWorks Therapeutics0.00%0.00%0.00%+0.45%+32.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.76-6.8%$2.11$0.87▼$6.37$299.59M0.991.22 million shs580,712 shsCRTXCortexyme$1.60$1.69$1.78▼$40.66$48.24M1.4620,672 shs88,479 shsEDITEditas Medicine$2.83+6.0%$2.74$0.91▼$4.12$240.09M2.161.14 million shs2.57 million shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/ASWTXSpringWorks Therapeutics$46.99$46.90$28.21▼$62.00$3.54B0.682.66 million shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-6.76%-1.43%+22.67%+89.04%-51.41%CRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%EDITEditas Medicine+5.99%+2.54%-6.60%+20.43%-26.11%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%SWTXSpringWorks Therapeutics0.00%0.00%0.00%+0.45%+32.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1750.97% UpsideCRTXCortexyme 0.00N/AN/AN/AEDITEditas Medicine 2.23Hold$5.1080.21% UpsideORTXOrchard Therapeutics 0.00N/AN/AN/ASWTXSpringWorks Therapeutics 2.00Hold$50.006.41% UpsideCurrent Analyst Ratings BreakdownLatest CRTX, EDIT, SWTX, ALEC, and ORTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.008/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $5.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $6.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.50(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M2.78N/AN/A$1.29 per share2.14CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AEDITEditas Medicine$32.31M7.88N/AN/A$1.63 per share1.74ORTXOrchard Therapeutics$22.66M16.77N/AN/A$7.74 per share2.16SWTXSpringWorks Therapeutics$191.59M18.48N/AN/A$6.47 per share7.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)CRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AEDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)ORTXOrchard Therapeutics-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/ASWTXSpringWorks Therapeutics-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%N/ALatest CRTX, EDIT, SWTX, ALEC, and ORTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AORTXOrchard TherapeuticsN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78CRTXCortexymeN/A9.929.92EDITEditas MedicineN/A2.772.77ORTXOrchard Therapeutics0.203.122.98SWTXSpringWorks TherapeuticsN/A4.334.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%CRTXCortexyme63.18%EDITEditas Medicine71.90%ORTXOrchard Therapeutics29.90%SWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipALECAlector9.70%CRTXCortexyme27.90%EDITEditas Medicine1.90%ORTXOrchard Therapeutics2.91%SWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableEDITEditas Medicine23089.92 million88.21 millionOptionableORTXOrchard Therapeutics16622.76 million22.10 millionOptionableSWTXSpringWorks Therapeutics23075.35 million69.45 millionOptionableCRTX, EDIT, SWTX, ALEC, and ORTX HeadlinesRecent News About These CompaniesSpringWorks Therapeutics Receives European Commission Approval for OGSIVEO® (nirogacestat) as the First Treatment for Desmoid TumorsAugust 18, 2025 | quiverquant.comQEuropean Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid TumorsAugust 18, 2025 | globenewswire.comEuropean Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid TumorsAugust 18, 2025 | globenewswire.comEuropean Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 PatientsJuly 18, 2025 | quiverquant.comQSpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform NeurofibromasJuly 18, 2025 | quiverquant.comQEuropean Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNJuly 18, 2025 | globenewswire.comEuropean Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNJuly 18, 2025 | globenewswire.comSpringWorks Therapeutics Completes Merger and DelistingJuly 1, 2025 | tipranks.comSpringWorks Therapeutics Inc (SWTX) - Investing.comJune 28, 2025 | investing.comSpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, NirogacestatJune 24, 2025 | msn.comSpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EUJune 20, 2025 | quiverquant.comQSpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid TumorsJune 20, 2025 | globenewswire.comSPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTXJune 3, 2025 | businesswire.comSpringWorks Therapeutics (SWTX) Surged on Acquisition NewsMay 27, 2025 | msn.comSpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challengesMay 26, 2025 | investing.comSpringWorks Gets CHMP Nod for Mirdametinib in Rare DiseaseMay 26, 2025 | zacks.comSpringWorks gets EU endorsement for genetic disorder treatmentMay 23, 2025 | msn.comSpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PNMay 23, 2025 | globenewswire.comSpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2025 | zacks.comHC Wainwright & Co. Downgrades SpringWorks Therapeutics (SWTX)May 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRTX, EDIT, SWTX, ALEC, and ORTX Company DescriptionsAlector NASDAQ:ALEC$2.76 -0.20 (-6.76%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.78 +0.02 (+0.54%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Cortexyme NASDAQ:CRTX$1.60 0.00 (0.00%) As of 09/15/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.83 +0.16 (+5.99%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.89 +0.06 (+2.12%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Orchard Therapeutics NASDAQ:ORTXOrchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.SpringWorks Therapeutics NASDAQ:SWTXSpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
